Thrush, Babies, and Breastfeeding Sep 16, 2008
It's common for a woman who has had a cesarean section to develop candidiasis ... A baby can pick up a yeast infection when he or she passes through the birth canal if mom has vaginal candidiasis. (Suite101.com)
Natural History of HIV Sep 14, 2008
Candidiasis, the presence of Candida yeast in the oral cavity (oral thrush) or esophagus. Pneumonia secondary to Pneumocystis jiroveci (formerly Pneumocystis carinii). (Suite101.com)
Yeast Infections And Candidiasis Sep 3, 2008
This condition, called systemic candidiasis, can be responsible for many different health problems throughout the body. Is Systemic Candidiasis a New Disease ... Systemic candidiasis has probably existed for as long as we've been using antibiotics. (Suite101.com)
Novartis Takes $235 Million Charge After Stopping Trial Aug 29, 2008
Another compound acquired with NeuTec, Mycograb, continues in late-stage trials for the treatment of invasive candidiasis, a life-threatening fungal infection. (Reporting by Sam Cage and Rupert Pretterklieber; Editing by David Cowell). (ABC News -- Wire)
Vaccine Cures Dangerous Yeast Infections in Mice Aug 28, 2008
He said certain hospital procedures, such as gastrointestinal surgery, put people at a higher risk for invasive candidiasis ... If successful, Cutler thinks the vaccine might be used to reduce the risks of invasive candidiasis and might even help prevent vaginal yeast infections. (MEDLINEplus)
Probiotics benefit whole body: Study Aug 26, 2008
They are recommended by doctors and nutritionists, after a course of antibiotics, or as part of the treatment for gut related candidiasis, a fungal infection. There have been claims that probiotics strengthen the immune system to combat allergies, excessive alcohol intake, stress, exposure to toxic substances and other diseases. (Sify.com, India)
HUMIRA(R) (adalimumab) Data Show That Treating Early Rheumatoid Arthritis With Combination Treatment Resulted in Cost Savings From Improved Work Productivity Jun 13, 2008
Rheumatoid Arthritis is the Leading Cause of Work Disability in Europe PARIS, June 13 /PRNewswire-FirstCall/ -- New data announced today showed that treating patients with early, active rheumatoid arthritis (RA) with Abbott's HUMIRA(R) (adalimumab) and methotrexate (MTX) resulted in an indirect cost savings of euro 4,845 (or approximately USD$6,086 using exchange rates at the time of the study) per patient per year compared to MTX treatment alone. These cost savings were attributed to improved... (PR Newswire)
New Long-Term HUMIRA(R) (adalimumab) Data Show Up to Seven-Year Efficacy with Combination Treatment for Rheumatoid Arthritis Jun 13, 2008
PARIS, June 13 /PRNewswire-FirstCall/ -- Seven-year rheumatoid arthritis (RA) data from open-label extension studies show that treatment with Abbott's HUMIRA(R) (adalimumab) resulted in clinical remission among long-standing RA patients when used in combination with methotrexate (MTX). The percentage of patients achieving clinical remission continued to increase after two or more years of continuous treatment with combination therapy. (PR Newswire)
Data Show that Abbott's HUMIRA(R) (adalimumab) Reduced the Signs and Symptoms of Ankylosing Spondylitis Up to Three Years Jun 13, 2008
PARIS, June 13 /PRNewswire-FirstCall/ -- Abbott announced new data from the open-label extension of the ATLAS (Adalimumab Trial Evaluating Long-Term Efficacy and Safety in AS) phase III clinical trial, which showed HUMIRA(R) (adalimumab) reduced the signs and symptoms of ankylosing spondylitis (AS) for up to three years of treatment among 74 percent of patients tested. AS is a type of arthritis that primarily causes inflammation of the spine and the spinal joints. (PR Newswire)
Al Dente: When physicians and dentists talk May 23, 2008
The lack of saliva opens the door to opportunistic infections, usually candidiasis, which is also known as thrush or yeast infection. Dryness makes dentures slip and uncomfortable to wear. (Malden Observer, MA)
BioAlliance Pharma: Combined Ordinary and Extraordinary General Meeting on April 29th 2008 Mar 21, 2008
The company has launched its first portfolio product (Loramyc) in France and the compound is currently in Phase III clinical development in oropharyngeal candidiasis in the USA. In addition, two other innovative products are currently in Phase III clinical trials: acyclovir Lauriad in oral herpes (based on the same Lauriad muco-adhesive technology as Loramyc, which enables targeted release at the disease site) and doxorubicin Transdrug in primary liver cancer (based on the Transdrug... (BusinessWire)
Barrier Therapeutics Announces Top Management Succession Plan Jan 26, 2008
The first product is currently marketed as Vusion(r), and it is the only product thus far to be approved by the FDA for diaper dermatitis complicated by candidiasis ... 35% white petrolatum) Ointment, for diaper dermatitis complicated by documented candidiasis; and Solage(r) (mequinol 2. (Primezone Releases)
FDA Approves Additional Indication for Astellas' MYCAMINE(R) Jan 23, 2008
Jan. 23 /PRNewswire/ -- Astellas Pharma Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved their Supplemental New Drug Application (sNDA) seeking approval for the use of MYCAMINE(R) (micafungin sodium) for Injection in the treatment of patients with Candidemia, Acute Disseminated Candidiasis, Candida Peritonitis and Abscesses. MYCAMINE was approved in 2005 for the treatment of patients with esophageal candidiasis and is the only echinocandin approved for the... (PR Newswire)
Glaxo says Advair shows edge over Spiriva in COPD Dec 28, 2007
Candidiasis was also reported more often in the Advair group (6 percent) than the Spiriva group (3 percent). Advair, which is also sold as Seretide, is Glaxo's biggest product, with 2006 sales of 3. (ABC News -- Wire)
Immtech and BioAlliance Sign Licensing Agreement for Pafuramidine Dec 5, 2007
The company has launched its first portfolio product (Loramyc(R)) in France, which is currently in Phase III clinical development in oropharyngeal candidiasis in the USA. In addition, two other innovative products are currently in phase III clinical trials: acyclovir Lauriad(R) in oral herpes (based on the same Lauriad(R) muco-adhesive technology as Loramyc(R), which enables targeted release at the disease site) and doxorubicin Transdrug(R) in primary liver cancer (based on the Transdrug(R)... (PR Newswire)
Barrier Therapeutics Announces Positive Results of Dose Escalation Clinical Safety Study With Pramiconazole Nov 27, 2007
Previously, the Company has also shown positive results in Phase 2a trials with pramiconazole in tinea pedis (athlete's foot), tinea corporis (ring worm), tinea cruris (jock itch), tinea versicolor, vaginal candidiasis and seborrheic dermatitis ... 35% white petrolatum) Ointment, for diaper dermatitis complicated by documented candidiasis; and Solage(r) (mequinol 2. (Primezone Releases)
Barrier Therapeutics to Present At the Acumen BioFin Rodman & Renshaw Healthcare Conference On November 6, 2007 Oct 29, 2007
35% white petrolatum) Ointment, for diaper dermatitis complicated by documented candidiasis; and Solage(r) (mequinol 2. 0%, tretinoin 0. (Primezone Releases)
Fungal Pneumonia: Opportunistic Oct 14, 2007
Pulmonary Candidiasis, Aspergillosis, Cryptococcosis & Mucormycosis ... Pulmonary Candidiasis. (Suite101.com)
Anidulafungin and Fluconazole for Candidiasis Sep 27, 2007
To the Editor: The study of anidulafungin as compared with fluconazole for invasive candidiasis by Reboli et al. (June 14 issue)1 shows the challenges involved in the design and reporting of noninferiority trials. 2,3 First, the dose of fluconazole may have been inadequate. (New England Journal of Medicine)
Hallucinations not unusual with antifungal therapy Sep 22, 2007
Voriconazole, sold under the trade name Vfend, is a relatively new drug used to treat serious fungus infections, such as invasive mold infections and invasive candidiasis. Many of these patients are extremely ill and are receiving several different drugs, which makes it difficult to distinguish the side effects of specific drugs from the symptoms of the underlying illness. (Scientific American)
BioDelivery Sciences International Sep 11, 2007
Sirgo says he expects the company to add roughly a half-dozen employees as it ratchets up clinical development for the next two drugs in its pipeline: BEMA LA, an acute pain drug, and Bioral Amphotericin B, a treatment for fungal infections that the company thinks will be effective in fighting an esophageal infection called esophageal candidiasis. The company plans to have BEMA LA in phase III trials by the end of 2008, Sirgo says, while Bioral Amphotericin B could enter phase II studies. (Triangle Business Journal)
Anacor Files Registration Statement for Initial Public Offering Sep 1, 2007
In addition, Anacor has a portfolio of other topical product candidates in development for the treatment of psoriasis, gingivitis, acne, vaginal candidiasis and tinea pedis. SOURCE Anacor Pharmaceuticals. (PR Newswire)
Three Studies Suggest Abbott's HUMIRA(R) (adalimumab) May Improve Work Productivity in Patients with Rheumatoid Arthritis Jun 15, 2007
One Groundbreaking Study Showed 11 Percent Fewer RA Patients Reported Job Loss When Treated With HUMIRA Combination Therapy Compared to Methotrexate Alone BARCELONA, Spain, June 15 /PRNewswire-FirstCall/ -- Rheumatoid arthritis (RA) is one of the most common causes of disability in the Western world. New data released today show that rheumatoid arthritis (RA) patients treated with Abbott's HUMIRA(R) (adalimumab) stayed working longer, had fewer absences and reported greater improvements in work... (PR Newswire)
Older antifungal still a good choice against tough infections Jun 14, 2007
The first compound used to treat candidiasis (yeast infection) was amphotericin B, which was effective but was limited by side effects ... Although expert guidelines issued in 2004 state that all of the above classes of drugs are appropriate to treat candidiasis, in reality, fluconazole was the one most prescribed ... For the new study, adults with invasive candidiasis were randomly assigned to receive anidulafungin or fluconazole. (Atlanta Journal-Constitution -- Health)
Echinocandins — First-Choice or First-Line Therapy for Invasive Candidiasis? Jun 14, 2007
NEJM -- Echinocandins -- First-Choice or First-Line Therapy for Invasive Candidiasis ... Echinocandins First-Choice or First-Line Therapy for Invasive Candidiasis ... The newest class of antifungal agents was heralded by the approval of caspofungin for candidiasis in 2002, and already. (New England Journal of Medicine)
Anidulafungin versus Fluconazole for Invasive Candidiasis Jun 14, 2007
We compared anidulafungin with fluconazole in a randomized, double-blind, noninferiority trial of treatment for invasive candidiasis. Methods Adults with invasive candidiasis were randomly assigned to receive either intravenous anidulafungin or intravenous fluconazole ... Conclusions Anidulafungin was shown to be noninferior to fluconazole in the treatment of invasive candidiasis. (New England Journal of Medicine)
Natural cure could work May 22, 2007
Lowering your intake of white refined sugar may reduce your risk of yeast and fungal infections like athlete's foot, toenail fungus, jock itch and vaginal candidiasis. Drink water, as soda pop is loaded with sugar. (Shoals TimesDaily)
Diagnosis of invasive candidiasis by enzyme-linked immunosorbent assay using the N-terminal fragment of Candida albicans hyphal wall protein 1 Apr 22, 2007
The diagnosis of invasive candidiasis is difficult because there are no specific clinical manifestations of the disease and colonization and infection are difficult to distinguish. In the last decade, much effort has been made to develop reliable tests for rapid diagnosis of invasive candidiasis, but none of them have found widespread clinical use ... Antibodies against a recombinant N-terminal fragment of the Candida albicans germ tube-specific antigen hyphal wall protein 1 (Hwp1) generated in... (BioMed Central)
Bacterial vaginosis Apr 14, 2007
The term vaginitis suggests an infection associated with the presence of inflammatory cells (neutrophils), commonly seen in vulvovaginal candidiasis or Trichomonas vaginalis infections. Bacterial vaginosis is diagnosed by clinical symptoms and laboratory microscopic examination of vaginal fluids (Gram stain). (Suite101.com)
Scientific Results Presented At ECCMID Demonstrate Well-Differentiated Profile of Basilea's Two Phase III Anti-infective Compounds Apr 3, 2007
Basilea's antifungal isavuconazole for the potential treatment of invasive fungal infections is in phase III testing in a global trial program in patients with invasive candidiasis including candidemia and patients with proven or probable aspergillosis. New microbiological surveillance data relevant for the treatment of candidemia demonstrated isavuconazole's superior coverage of different candida species and most fluconazole-resistant isolates compared to other azole drugs (P1978). (Primezone Releases)
Researcher Finds New Way To Treat Devastating Fungal Infections Mar 6, 2007
He treated Candida albicans, often seen as esophageal candidiasis, an infection prevalent in HIV/AIDS and cancer patients receiving chemotherapy, and aspergillosis, an infection caused by aspergillus fumigatis, a family of common moulds that can cause symptoms ranging from cough to brain damage ... A form of invasive candidiasis called candidemia is the fourth most common bloodstream infection among hospitalized patients in the U.S. A survey conducted at CDCP found that candidemia occurs in... (Science Daily)
BDSI given OK to start human testing on drug delivery technology Feb 4, 2007
The first Bioral product to be tested is an oral version of Amphotericin B, an antifungicidal agent for treating infections such as esophageal candidiasis, an infection prevalent in HIV patients and many patients receiving cancer chemotherapy. Mark Sirgo, CEO of BDSI (Nasdaq: BDSI), said the human trials will begin in 2007 but the 15-employee company has yet to set an exact date. (Raleigh Triangle Business Journal, NC)
Sugar Diabetes Jan 30, 2007
Fatigue, reduction of energy levels, vision problems, constant thirst, muscle weakness, atherosclerosis, kidney failure, frequent urination, cystitis, candidiasis (fungus infections), tingling and numbness in hands and feet, foot infections, and high blood pressure are all symptoms of diabetes and should be checked if one or more are present. If sugar levels are not regulated they can cause symptomatic problems and complications with the eyes, muscles, kidneys and bladder and cardiovascular... (Suite101.com)
The New England Journal Of Medicine Publishes Two Landmark Studies Of NOXAFIL(R) (Posaconazole) in the Prevention of Invasive Fungal Infections Jan 25, 2007
NOXAFIL also was approved in the United States and EU in 2006 for the treatment of oropharyngeal candidiasis (OPC), a fungal infection of the mouth and throat, and in the EU in 2005 and Australia in 2006 for the treatment of certain IFIs in adult patients with disease that is refractory to or in patients who are intolerant of certain commonly used antifungal agents ... The product label should be consulted when other drugs are prescribed with NOXAFIL. In clinical studies of oropharyngeal... (PR Newswire)
Coping with HIV| Jan 11, 2007
Candidiasis, or thrush, is common in HIV-positive patients, and is an Aids-defining condition ... People with Aids are at risk of developing disseminated candidiasis, in which the fungus spreads through the body. (iAfrica.com)
